Menu
Search
|

Menu

Close
X

XOMA Corp XOMA.OQ (NASDAQ Stock Exchange Global Market)

18.74 USD
-0.05 (-0.27%)
As of 5:20 PM BST
Previous Close 18.79
Open 18.67
Volume 1,744
3m Avg Volume 24,903
Today’s High 18.74
Today’s Low 18.16
52 Week High 20.29
52 Week Low 11.10
Shares Outstanding (mil) 8.72
Market Capitalization (mil) 161.92
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY19
8
FY18
5
FY17
53
FY16
6
EPS (USD)
FY19
0.208
FY18
-1.594
FY17
-0.455
FY16
-8.881
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
12.49
7.90
Price to Book (MRQ)
vs sector
6.74
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
93.98
17.64
LT Debt to Equity (MRQ)
vs sector
86.79
12.61
Return on Investment (TTM)
vs sector
-11.89
12.69
Return on Equity (TTM)
vs sector
-51.61
17.13

EXECUTIVE LEADERSHIP

W. Denman Van Ness
Lead Independent Chairman of the Board, Since 2011
Salary: --
Bonus: --
James Neal
Chief Executive Officer, Chief Operating Officer, Director, Since 2016
Salary: $354,165.00
Bonus: $132,384.00
William Garrard
Chief Financial Officer, Vice President - Finance, Since 2015
Salary: $274,749.00
Bonus: $87,380.00
Danny Hart
Vice President, General Counsel, Since 2018
Salary: --
Bonus: --
Dee Datta
Chief Business Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2200 Powell St Ste 310
EMERYVILLE   CA   94608-1818

Phone: +1510.2047239
Site: www.xoma.com

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.

SPONSORED STORIES